NNC0721-8060
DrugNNC0721-8060 will be administered subcutaneously.
NCT Number: NCT07767175
The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
Interested in participating?
Request Info18 year–55 year
All sexes
Interventional
Phase 1
ICON Early Phase Services, LLC, Lenexa, Kansas, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
NNC0721-8060 will be administered subcutaneously.
Semaglutide will be administered subcutaneously.
Placebo will be administered subcutaneously.
Time frame: From Day 1 to Day 36
Measured as number of events.
Time frame: From Day 1 to Day 57
Measured as number of events.
Time frame: From Day 1 to Day 85
Measured as percentage change in body weight.
Time frame: From Day 1 to Day 36
Measured as hour nanomoles per litre (h*nmol/L).
Time frame: From Day 1 to Day 36
Measured as nanomoles per litre (nmol/L).
Time frame: From Day 1 to Day 57
Measured as h*nmol/L.
Time frame: From Day 1 to Day 57
Measured as nmol/L.
Time frame: From Day 1 to Day 113
Measured as h*nmol/L.
Time frame: From Day 1 to Day 113
Measured as nmol/L.
Time frame: From Day 1 to Day 113
Measured as number of events.
Interested in participating?
Request InfoNovo Nordisk A/S
Industry
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07752979
Body Weight, Nutrition Disorders
Scottsdale, Arizona, United States
View Trial DetailsNCT07754474
Body Weight, Nutrition Disorders
Mannheim, Germany
View Trial DetailsNCT07803744
Autoimmune Diseases, Body Weight
Miami, Florida, United States
View Trial DetailsNCT07369011
Apnea, Body Weight
Cullman, Alabama, United States
View Trial Details